Canada has made history as the first G7 country to approve generic versions of Ozempic, the blockbuster weight-loss and diabetes drug, with lower-cost alternatives already beginning to roll out in pharmacies across the country. The development is prompting renewed debate about why American patients continue to pay significantly more for the same medication.
What Is Generic Ozempic?
Ozempic, whose active ingredient is semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Danish pharmaceutical giant Novo Nordisk. Originally approved for the treatment of type 2 diabetes, it gained widespread attention for its effectiveness in supporting weight loss, fuelling a global surge in demand.
Generic versions contain the same active compound but are produced by competing manufacturers once patents expire or are successfully challenged, dramatically reducing production costs and consumer prices. In Canada, the approval of these generics means that patients can now access semaglutide-based treatment at a fraction of the brand-name cost.
Why Is the US Falling Behind?
The United States has not yet approved a generic version of Ozempic, and the reasons are multifaceted. Patent protections in the US extend the market exclusivity period for Novo Nordisk’s branded products, while the regulatory pathway for complex biologics and injectable drugs is more demanding than for standard small-molecule generics.
The US Food and Drug Administration requires rigorous clinical equivalency data before approving biosimilars and complex generics — a process that can take years and cost manufacturers hundreds of millions of dollars. Critics argue that the US system creates structural barriers that keep drug prices artificially high.
The Cost Gap and Patient Impact
The price disparity is stark. In the United States, a monthly supply of branded Ozempic can cost over $900 without insurance coverage. Canadian patients, by contrast, are set to benefit from competitive pricing as multiple generic manufacturers enter the market.
Health advocates in the US have pointed to Canada’s approval as further evidence that more affordable access to obesity and diabetes treatments is achievable within a regulatory framework that still prioritises safety and efficacy. With obesity rates remaining high across North America and demand for GLP-1 drugs continuing to outstrip supply, the question of affordable access has taken on fresh urgency.
For now, American patients watching Canada’s rollout will be hoping that regulatory progress and political will can close the gap — before their health, and their wallets, pay the price of delay.
